1. Home
  2. REVBW vs PWUPU Comparison

REVBW vs PWUPU Comparison

Compare REVBW & PWUPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVBW
  • PWUPU
  • Stock Information
  • Founded
  • REVBW N/A
  • PWUPU N/A
  • Country
  • REVBW United States
  • PWUPU
  • Employees
  • REVBW 9
  • PWUPU N/A
  • Industry
  • REVBW Biotechnology: Pharmaceutical Preparations
  • PWUPU
  • Sector
  • REVBW Health Care
  • PWUPU
  • Exchange
  • REVBW Nasdaq
  • PWUPU NYSE
  • Market Cap
  • REVBW N/A
  • PWUPU N/A
  • IPO Year
  • REVBW 2020
  • PWUPU N/A
  • Fundamental
  • Price
  • REVBW $0.01
  • PWUPU $11.44
  • Analyst Decision
  • REVBW
  • PWUPU
  • Analyst Count
  • REVBW 0
  • PWUPU 0
  • Target Price
  • REVBW N/A
  • PWUPU N/A
  • AVG Volume (30 Days)
  • REVBW N/A
  • PWUPU N/A
  • Earning Date
  • REVBW N/A
  • PWUPU N/A
  • Dividend Yield
  • REVBW N/A
  • PWUPU N/A
  • EPS Growth
  • REVBW N/A
  • PWUPU N/A
  • EPS
  • REVBW N/A
  • PWUPU N/A
  • Revenue
  • REVBW N/A
  • PWUPU N/A
  • Revenue This Year
  • REVBW N/A
  • PWUPU N/A
  • Revenue Next Year
  • REVBW N/A
  • PWUPU N/A
  • P/E Ratio
  • REVBW N/A
  • PWUPU N/A
  • Revenue Growth
  • REVBW N/A
  • PWUPU N/A
  • 52 Week Low
  • REVBW N/A
  • PWUPU N/A
  • 52 Week High
  • REVBW N/A
  • PWUPU N/A
  • Technical
  • Relative Strength Index (RSI)
  • REVBW N/A
  • PWUPU 37.08
  • Support Level
  • REVBW N/A
  • PWUPU $11.41
  • Resistance Level
  • REVBW N/A
  • PWUPU $11.44
  • Average True Range (ATR)
  • REVBW 0.00
  • PWUPU 0.05
  • MACD
  • REVBW 0.00
  • PWUPU -0.01
  • Stochastic Oscillator
  • REVBW 0.00
  • PWUPU 0.00

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About PWUPU POWERUP ACQUISITION CORP UNIT 1 COM CL A & 1/2 RED WT(18/02/2032)

PowerUp Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: